54
ҵᝨसٙ
ߤ
ΪɿႭӺ
ڌ
(2004)
d
IL-1
ၾҵ
ᝨसٙ೯͛೯࢝ᗫf
IL-1
ձƹ
-
ʍᓔ९ዢ
ܓ
ٙʺ৷
ၾҵᝨसٙ
ת
Ҥձᘌࠠ
ܓ
ᗫfԨ˲ਗ
ي
ྼ᜕೯
ତ
(2005)
d
ڗ
ಂձᏐዧೌпҵᝨਗ
ي
ٙʕᅹձ̮մ
IL-1
ƺʺ৷dԨ˲Ꮠዧ
ءۃ
ɝ
IL-1
աܶҤኒঐ
ڜ
ᓙ
ਗ
ي
ҵᝨᅵБ
މ
ٙପ͛fӺ
(2005)
ᒔᝈ࿀Ց
ߤ
Ϊ
ɿ
ط
ᐕ̙ኬ
ߧ
ҵᝨसfν
IFN
ƹႰኬٙ
IL-6
ձ
IL-8
ᄣ
̋dၾҵᝨसًᜑഹᗫf
白介素與保健
ͣ͟ʧ९ՈϞ࿁е
ޥ
ᏐഈʔΝ
ܓ
ٙʍཫЪ͜d
Ͼί
ڭ
ɪɰϞɓ֛ٙᅂᚤf
ɓe
IL-2
ίථ
ٺ
ጟ㹻
(PSP
ձ
PSK)
ҤᐖʕٙЪ͜
1993
ϋуϞӺజ༸၈jථ
ٺ
ጟ㹻
PSP(Polysaccharide
peptide)
̙ᄣ੶͟
IL-2
ዧ
ݺ
ٙ૨ෆ
ߤ
͵у
LAK
ߤ
ٙᄣಟ
ݺ
dձ৷Չ૨ෆᐖ
ݺߤ
f
Ϟ̨ᝄኪ٫జ༸
(2009)
၈jථ
ٺ
εᒙ
PSK (Krestin)
̙˸ၾᠧlzٙ
IL-2
೯౨ΝЪ͜dᄣ̮̋մА૰ˋ
ߤ
ᄣ͛dࡡΪ݊ɚ٫ʱйഐΥί
NK
ߤ
ʔΝٙա
ɪdආϾႰኬʔΝٙৃࢹෂࢰ
ߧה
f
ɚe
IL-2
ίᜳ
ٺ
ҤᐖʕٙЪ͜
ʊϞʔˇజ༸၈dᜳ
ٺ
ঐ
ڮ
ආе
ޥ
ߤ
Υϓ
IL-2
eʍ
ᓔ९e໕ᆯᕸϥΪɿഃε
ߤ
Ϊɿٙପ͛d
ڮ
ආ
ˋ
ߤ
ٙᄣಟe৷̶አ
ߤ
e
NK
ߤ
e
T
ߤ
ٙчአঐɢձ૨ෆɢdϾ৷ԣᐖձҤᐖٙЪ͜f
ɧe
Il-2
ڮ
ආе
ߗޥ
աٙЪ͜
อ
ڐ
ٙӺ
ڌ
d
IL-2
ᒔ̙˸
ݺ
ʷ
Treg (CD25+FoxP3)
d
ϾҵՓ
T
ߤ
ཀ
ݺܓ
ʷdৎՑ
ڮ
ආе
ߗޥ
աٙЪ͜f
̬e
IL-10
ԣ
ط
ᜊ࿒ˀᏐशषձࡲఁ
ତʊ̈d̙˸મ͜ɓۨሜື
ߤ
(Trl)
ʿՉʱ
ؤ
ٙ
IL-10
ԣ
ط
ᜊ࿒ˀᏐशषձࡲఁdΪ
IL-10
˷̙˸
ɨሜˏ೯༈ᗳशषٙ
ࡈ
ᐑືd
ڌ
Trl
ɰ̙
ڜ
ҵ
Th2
ʧኬٙᑗґशषdԨϞᆑίٙᏐ͜
౻ۃ
f
ʞe
IL-17
ڜ
ᓙኒ
ط
ᐕІԒе
ޥ
ष
࠽
ء
จٙ݊d߅ኪʊ೯ତ
IL-17
࿁ІԒе
ޥ
षˏ
೯ٙኜ֜ฦෆৎഹࠠ
ࠅ
ٙ
ڮ
ආЪ͜d݊ყɪ͍
০࿁ක೯
ڜ
ᓙᖹ
ي
dɛ
މ
ҵՓ
IL-17
f
ʬe
IL-33
̙ঐϞп
ط
ᐕ໘ৗʷस
࠰
ಥ߅ɽٙਗ
ي
ྼ㤂Ӻ
(2016)
೯ତd
IL-33
̙ঐϞп
ط
ᐕ໘ৗʷसfΪ
IL-33
̙ಯˇषཽlzዠ४ᅵஐͣ
ڐ
ɓ̒dԨ̋ҞՉৰʿɽ໘
ف
सˀᏐf
ɖeͣʧ९ٙᑗґᏐ͜
Ꮠࠠ͜ଡ଼
ߤ
ΪɿЪ
މ
ᖹ
ي
͜शषٙ
ط
ᐕ၈
މ
ߤ
Ϊɿᐕ
ج
fί
ط
ᐕె໕ᆯeช
ݑ
e
ڮ
ආிА̌
ঐ
ܨ
ూഃʊ՟
ܘ
ɽආ࢝dՉʕϞɓҭਿΪࠠଡ଼Ϊ
ɿʊϓ
މ
͍όٙᖹ
ي
fϞɓԬʊආɝᑗґྼ᜕ච
ݬ
d
ν
IL-1a
e
IL-1b
ቇᏐस
׳މ
ᐕeʷᐕ
ߧה
ٙ৶ҵ
Փdె໕ᆯഃf˸ɨΝf
IL-3
৶স။eАʃؐ
ॹ˶eІԒ৶ಔഃf
IL-4
е
ޥ
ॹeె໕ᆯ
ഃf
IL-6
׳ᐕeʷᐕ
ߧה
ٙАʃؐಯˇeె໕ᆯ
ഃf
IL-11
Аʃؐಯˇसf
Interleukin & Health
T lymphocytes (a white blood cell) may be helper (Th: Th1 is for immunity; Th2, for allergic reactions) or regulatory (Treg, e.g., Tr1
inhibits self-inflammatory reactions and pathological responses against pathogens or transplants). Interleukin (IL: IL-1 to IL-33 with
diverse functions) is a vital cytokine (cell secretion). Clinically: (1) PSP of yunzhi stimulates killer cells for killing cancer cells; krestin
coops with our IL-2 to increase peripheral blood lymphocytes (2) Lingzhi boosts the synthesis of IL-2, interferon, tumor necrosis
factor and the proliferation of peripheral blood lymphocytes, enhances the phagocytic power of macrophages, natural killer cells (NK-
cells) and T-cells (3) IL-2 activates Treg: inhibiting excessive activities of T-cells (4) Using Tr1 and its IL-10 prevents chaotic immune
response diseases and asthma; inhibits Th2 mediated diseases (with a good prospect of clinical application) (5) As IL-17 is well
recognized to be related to auto-immune diseases, drug development is thus well underway (6) As IL-33 reduces amyloid changes in
laboratory animals, it may relieve dementia (7) As some recombinant cytokine preparations of IL are already in clinical use and others
are being tested clinically, the prospects of using IL clinically for treatments are tremendous!
專題探索
